Potential antidiabetic agents. Pyrazolo(3,4-b)pyridines.
D000818:Animals; D001786:Blood Glucose; D001921:Brain / Q000201:enzymology; D002415:Cats; D000242:Cyclic AMP; D003864:Depression, Chemical; D003920:Diabetes Mellitus / Q000097:blood / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009206:Myocardium / Q000201:enzymology; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011720:Pyrazoles / Q000138:chemical synthesis / Q000494:pharmacology; D011725:Pyridines / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D013311:Streptozocin; D013329:Structure-Activity Relationship; D013453:Sulfonylurea Compounds / Q000138:chemical synthesis / Q000494:pharmacology
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010726:Phosphodiesterase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D013453:Sulfonylurea Compounds; D013311:Streptozocin; D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases